Twitter LinkedIn YouTube iTune Podcast Google Podcasts Spotify

MedX Health Corp. TSXV: MDX

InvestorIntel Features on MedX Health Corp.

Mike Druhan on bringing MedX’s skin cancer detection technology to Brazil

In an InvestorIntel interview during PDAC last week, Tracy Weslosky secures an interview update with Vice President of Corporate Development Mike Druhan […]

Druhan on MedX Health’s skin cancer technology deployment deal (SIAScope) with exclusive Brazilian distributor

“Our system is a proper SaaS model. We have an optical scanner (SIAScopeTM) that will take an image of a […]

Has a revolution in early detection for deadly skin cancer begun?

Detecting deadly skin cancers such as malignant melanoma early is medical best practice these days. Doctors or clinics that rely […]

Company Overview

TeamWebsite

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

News Releases

View All News

Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify